May 11, 2022 • 8:00 am EDT Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
May 10, 2022 • 8:00 am EDT Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 8, 2022 • 1:05 pm EDT Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
Mar 11, 2022 • 8:05 am EST Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
Mar 8, 2022 • 8:05 am EST Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
Dec 7, 2021 • 8:05 am EST Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Nov 12, 2021 • 8:05 am EST Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Nov 11, 2021 • 8:05 am EST Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Aug 12, 2021 • 8:05 am EDT Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Jun 24, 2021 • 8:05 am EDT Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis